Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment

Published:2013-03-28 Issue:4 Volume:19 Page:e228-e238
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Farrugia A.,Cassar J.¹,Kimber M. C.²,Bansal M.²,Fischer K.³,Auserswald G.⁴,O'Mahony B.⁵,Tolley K.⁶,Noone D.⁵,Balboni S.²

Affiliation:

1. Faculty of Health; University of Canberra; Canberra; Australia

2. Plasma Protein Therapeutics Association; Annapolis; MD; USA

3. Van Creveldkliniek, University Medical Center Utrecht; Utrecht; The Netherlands

4. Ambulanz fuer Thrombose und Haemostasestoerungen Prof.- Hess Kinderklink; Klinikum Bremen-Mitte; Germany

5. Irish Haemophilia Society; Dublin; Ireland

6. Tolley Health Economics Ltd; Derbyshire; UK

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12121/fullpdf

Reference66 articles.

1. Pharmacotherapy of haemophilia A;Gringeri;Expert Opin Biol Ther,2011

2. How I treat age-related morbidities in elderly persons with hemophilia;Mannucci;Blood,2009

3. Modern haemophilia care;Berntorp;Lancet,2012

4. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?;Miners;Haemophilia,2012

5. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis;Devlin;Health Econ,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors;Advances in Therapy;2024-04-23

2. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany;PharmacoEconomics - Open;2024-03-23

3. Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies;PharmacoEconomics;2023-08-18

4. Expectation and loss when gene therapy for haemophilia is not an option: An exigency sub‐study;Haemophilia;2023-03-07

5. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study;Orphanet Journal of Rare Diseases;2022-04-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3